Concepts (175)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 24 | 2024 | 4946 | 1.140 |
Why?
|
| Anti-HIV Agents | 13 | 2024 | 1275 | 1.070 |
Why?
|
| Anti-Retroviral Agents | 8 | 2023 | 542 | 0.870 |
Why?
|
| Child | 21 | 2024 | 2180 | 0.610 |
Why?
|
| Piperazines | 4 | 2024 | 73 | 0.510 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 4 | 2024 | 76 | 0.500 |
Why?
|
| Pyridones | 4 | 2024 | 87 | 0.500 |
Why?
|
| Ritonavir | 4 | 2020 | 137 | 0.490 |
Why?
|
| Alanine | 2 | 2024 | 29 | 0.420 |
Why?
|
| Child, Preschool | 14 | 2024 | 1675 | 0.420 |
Why?
|
| HIV-1 | 6 | 2021 | 1239 | 0.410 |
Why?
|
| Emtricitabine | 2 | 2024 | 74 | 0.410 |
Why?
|
| Male | 21 | 2024 | 6489 | 0.400 |
Why?
|
| Tenofovir | 2 | 2024 | 158 | 0.390 |
Why?
|
| Humans | 28 | 2024 | 14077 | 0.370 |
Why?
|
| Lopinavir | 3 | 2020 | 137 | 0.350 |
Why?
|
| Female | 21 | 2024 | 8751 | 0.350 |
Why?
|
| Viral Load | 10 | 2024 | 808 | 0.320 |
Why?
|
| Dideoxynucleosides | 2 | 2020 | 29 | 0.320 |
Why?
|
| South Africa | 18 | 2024 | 7312 | 0.300 |
Why?
|
| Amides | 2 | 2024 | 8 | 0.280 |
Why?
|
| Infectious Disease Transmission, Vertical | 5 | 2022 | 467 | 0.270 |
Why?
|
| Pneumonia | 2 | 2021 | 127 | 0.270 |
Why?
|
| Growth Disorders | 3 | 2020 | 56 | 0.250 |
Why?
|
| Oxazines | 2 | 2022 | 71 | 0.240 |
Why?
|
| Infant | 9 | 2022 | 2145 | 0.230 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 4 | 0.230 |
Why?
|
| Adenine | 1 | 2024 | 88 | 0.220 |
Why?
|
| Sleep Wake Disorders | 1 | 2023 | 10 | 0.220 |
Why?
|
| Microbiota | 1 | 2023 | 30 | 0.210 |
Why?
|
| Treatment Outcome | 6 | 2023 | 867 | 0.200 |
Why?
|
| Caregivers | 1 | 2022 | 66 | 0.200 |
Why?
|
| Adolescent | 7 | 2024 | 2858 | 0.200 |
Why?
|
| HIV Protease Inhibitors | 2 | 2021 | 92 | 0.190 |
Why?
|
| HIV Integrase Inhibitors | 1 | 2021 | 29 | 0.190 |
Why?
|
| Case-Control Studies | 5 | 2021 | 464 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2021 | 55 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 186 | 0.180 |
Why?
|
| Movement Disorders | 1 | 2020 | 2 | 0.180 |
Why?
|
| Problem Behavior | 1 | 2020 | 6 | 0.180 |
Why?
|
| AIDS Dementia Complex | 1 | 2020 | 29 | 0.180 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 22 | 0.180 |
Why?
|
| Brain | 1 | 2020 | 53 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2021 | 194 | 0.170 |
Why?
|
| Mitochondria | 1 | 2019 | 12 | 0.170 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 31 | 0.170 |
Why?
|
| Epigenesis, Genetic | 1 | 2019 | 17 | 0.170 |
Why?
|
| Sustained Virologic Response | 1 | 2019 | 22 | 0.160 |
Why?
|
| Drug Therapy, Combination | 4 | 2021 | 271 | 0.160 |
Why?
|
| Educational Status | 1 | 2019 | 68 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 260 | 0.160 |
Why?
|
| Coinfection | 1 | 2021 | 268 | 0.160 |
Why?
|
| Rifampin | 1 | 2020 | 189 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2019 | 26 | 0.160 |
Why?
|
| Quality of Life | 1 | 2020 | 170 | 0.160 |
Why?
|
| Atazanavir Sulfate | 1 | 2018 | 10 | 0.150 |
Why?
|
| Growth | 1 | 2018 | 14 | 0.150 |
Why?
|
| Lipids | 1 | 2018 | 81 | 0.150 |
Why?
|
| Unsafe Sex | 1 | 2018 | 45 | 0.150 |
Why?
|
| Bayes Theorem | 3 | 2022 | 77 | 0.150 |
Why?
|
| Cohort Studies | 5 | 2019 | 939 | 0.150 |
Why?
|
| Aging | 1 | 2018 | 109 | 0.140 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2022 | 507 | 0.140 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2021 | 654 | 0.140 |
Why?
|
| Body Composition | 1 | 2018 | 150 | 0.140 |
Why?
|
| Stavudine | 1 | 2017 | 78 | 0.140 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2020 | 320 | 0.140 |
Why?
|
| Drug Combinations | 3 | 2024 | 41 | 0.140 |
Why?
|
| Child of Impaired Parents | 1 | 2016 | 9 | 0.140 |
Why?
|
| Truth Disclosure | 1 | 2016 | 18 | 0.130 |
Why?
|
| Communication | 1 | 2016 | 56 | 0.130 |
Why?
|
| Logistic Models | 3 | 2022 | 252 | 0.120 |
Why?
|
| HIV | 1 | 2017 | 380 | 0.120 |
Why?
|
| Infant, Newborn | 4 | 2022 | 1410 | 0.110 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 409 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2022 | 767 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2012 | 2 | 0.100 |
Why?
|
| Virus Latency | 1 | 2012 | 5 | 0.100 |
Why?
|
| RNA, Viral | 3 | 2019 | 303 | 0.090 |
Why?
|
| Influenza Vaccines | 1 | 2013 | 132 | 0.090 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 266 | 0.090 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 263 | 0.090 |
Why?
|
| Cross-Sectional Studies | 3 | 2020 | 1377 | 0.090 |
Why?
|
| Pregnancy | 3 | 2022 | 1815 | 0.090 |
Why?
|
| Alkynes | 2 | 2021 | 113 | 0.090 |
Why?
|
| Cyclopropanes | 2 | 2021 | 119 | 0.090 |
Why?
|
| Benzoxazines | 2 | 2021 | 119 | 0.080 |
Why?
|
| DNA Methylation | 2 | 2019 | 19 | 0.080 |
Why?
|
| Influenza, Human | 1 | 2013 | 360 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2022 | 217 | 0.070 |
Why?
|
| Adult | 3 | 2023 | 5664 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 367 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 153 | 0.060 |
Why?
|
| Hospitalization | 2 | 2021 | 392 | 0.060 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2019 | 145 | 0.060 |
Why?
|
| Biomarkers | 2 | 2018 | 322 | 0.060 |
Why?
|
| Thailand | 1 | 2024 | 24 | 0.060 |
Why?
|
| United States | 1 | 2024 | 129 | 0.060 |
Why?
|
| Uganda | 1 | 2024 | 194 | 0.060 |
Why?
|
| Disease Progression | 2 | 2014 | 154 | 0.050 |
Why?
|
| Standard of Care | 1 | 2023 | 28 | 0.050 |
Why?
|
| Mouth | 1 | 2023 | 8 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 18 | 0.050 |
Why?
|
| Machine Learning | 1 | 2022 | 19 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2022 | 23 | 0.050 |
Why?
|
| Self Report | 1 | 2022 | 111 | 0.050 |
Why?
|
| World Health Organization | 1 | 2022 | 134 | 0.050 |
Why?
|
| Cholesterol | 1 | 2021 | 38 | 0.050 |
Why?
|
| Algorithms | 1 | 2022 | 105 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2021 | 113 | 0.050 |
Why?
|
| Drug Dosage Calculations | 1 | 2021 | 8 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 18 | 0.050 |
Why?
|
| Child Health | 1 | 2021 | 76 | 0.050 |
Why?
|
| Health Personnel | 1 | 2022 | 229 | 0.040 |
Why?
|
| Biological Availability | 1 | 2020 | 43 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 30 | 0.040 |
Why?
|
| CpG Islands | 1 | 2019 | 6 | 0.040 |
Why?
|
| Education | 1 | 2019 | 22 | 0.040 |
Why?
|
| Disease Transmission, Infectious | 1 | 2019 | 39 | 0.040 |
Why?
|
| Receptors, KIR3DL1 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2019 | 10 | 0.040 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 25 | 0.040 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 1 | 2019 | 20 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 24 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 43 | 0.040 |
Why?
|
| Receptors, KIR | 1 | 2019 | 23 | 0.040 |
Why?
|
| Developing Countries | 1 | 2021 | 385 | 0.040 |
Why?
|
| Telomere | 1 | 2018 | 17 | 0.040 |
Why?
|
| Receptors, CCR5 | 1 | 2019 | 54 | 0.040 |
Why?
|
| Powders | 1 | 2018 | 7 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2018 | 22 | 0.040 |
Why?
|
| Exposure to Violence | 1 | 2018 | 2 | 0.040 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 34 | 0.040 |
Why?
|
| Cytokines | 1 | 2019 | 107 | 0.040 |
Why?
|
| Child Abuse | 1 | 2018 | 10 | 0.040 |
Why?
|
| Domestic Violence | 1 | 2018 | 8 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 150 | 0.040 |
Why?
|
| DNA, Viral | 1 | 2019 | 165 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2018 | 49 | 0.040 |
Why?
|
| Dyslipidemias | 1 | 2018 | 47 | 0.040 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2018 | 113 | 0.040 |
Why?
|
| Adolescent Behavior | 1 | 2018 | 58 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2018 | 119 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2020 | 299 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 430 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 210 | 0.040 |
Why?
|
| Risk Factors | 1 | 2021 | 1431 | 0.040 |
Why?
|
| Lamivudine | 1 | 2017 | 86 | 0.030 |
Why?
|
| Mental Health | 1 | 2018 | 86 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 1131 | 0.030 |
Why?
|
| Sexual Partners | 1 | 2018 | 211 | 0.030 |
Why?
|
| HIV Antibodies | 1 | 2019 | 243 | 0.030 |
Why?
|
| Child Health Services | 1 | 2016 | 33 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 532 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2018 | 312 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 45 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 103 | 0.030 |
Why?
|
| Age Factors | 1 | 2014 | 364 | 0.030 |
Why?
|
| Hemagglutination Inhibition Tests | 1 | 2013 | 23 | 0.030 |
Why?
|
| Virus Shedding | 1 | 2013 | 24 | 0.030 |
Why?
|
| Influenza A virus | 1 | 2013 | 28 | 0.030 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2013 | 31 | 0.030 |
Why?
|
| Influenza B virus | 1 | 2013 | 42 | 0.030 |
Why?
|
| Acetylation | 1 | 2012 | 2 | 0.030 |
Why?
|
| Proviruses | 1 | 2012 | 6 | 0.030 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2012 | 3 | 0.030 |
Why?
|
| Histones | 1 | 2012 | 7 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2013 | 54 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2012 | 11 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2012 | 23 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2013 | 263 | 0.030 |
Why?
|
| Phylogeny | 1 | 2013 | 231 | 0.020 |
Why?
|
| Viremia | 1 | 2012 | 66 | 0.020 |
Why?
|
| Young Adult | 1 | 2018 | 2357 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2013 | 468 | 0.020 |
Why?
|